All studies
Phase 3RecruitingInterventionalNCT07784725

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus (SELENE 1)

A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity Without Type 2 Diabetes Mellitus (SELENE 1)

  • Obesity or Overweight
I want to take partRefer a patient14 sites in India (12 recruiting) · 220 worldwide

At a glance

Phase
Phase 3
Study type
Interventional
Sponsor
AstraZeneca
Enrolment target
2,500
Started
19 August 2026
Main results due (estimated)
11 August 2028
Study ends (estimated)
21 May 2029
Allocation
Randomized
Design
Parallel
Purpose
Treatment
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Sites
220 · 14 in India
First posted
25 August 2026
Registry updated
30 October 2026

International, multi-centre, randomised, double-blind, placebo-controlled, parallel-group

Can you take part?

  • Aged 18 years and over.
  • Open to any sex.
  • You need the condition being studied. Healthy volunteers are not accepted.

Age groups: adult, older adult.

These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.

Read the full eligibility criteria
Inclusion Criteria:

* Males \& females (inclusive of all gender identities) age ≥18 years
* BMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with at least one of the following weight related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, heart failure, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, osteoarthritis of the knee, or stress urinary incontinence
* Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation
* History of at least one self-reported unsuccessful attempt to lose body weight in their lifetime

Exclusion Criteria:

* Obesity primarily caused by other endocrine disorders
* History of Type 1 or Type 2 Diabetes Mellitus, HbA1c ≥6.5% (48 mmol/mol), and/or treatment with glucose-lowering agent(s) within 3 months prior to Screening
* Significant hepatobiliary disease and/or any of the following results at Screening:

  * ALT ≥ 3.0 × ULN
  * AST ≥ 3.0 × ULN
  * TBL \> 1.5 × ULN (except for cases of known Gilbert's Syndrome)
* Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation.

What this study is about

In the sponsor’s own words, from the registry.

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

Read the detailed description

This is a Phase III, global, randomised, parallel-group, double-blind, multicentre study to assess the efficacy and safety of AZD6234 compared with placebo, administered SC once weekly in adults with obesity or overweight with at least one weight-related comorbidity without T2DM. Eligible participants will be randomized to either receive AZD6234 or matching placebo respectively.

Keywords: Obesity · Overweight · AZD6234 · Lenbelintide

What participants receive

  • Experimental

    AZD6234 Dose 1

    AZD6234 Dose 1

    Drug: Lenbelintide

  • Experimental

    AZD6234 Dose 2

    AZD6234 Dose 2

    Drug: Lenbelintide

  • Placebo comparator

    Placebo

    Matching placebo

    Drug: Placebo

Interventions

  • LenbelintideDrug

    Also known as AZD6234

    IMP injected subcutaneously, once a week. Unit dose strength as per CSP.

  • PlaceboDrug

    Placebo matching IMP dose injected subcutaneously, once a week.

What the study measures

Primary outcomes

  1. Percent change in body weight from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo in percent body weight change

    Time frame: 68 weeks

Secondary outcomes

  1. Absolute change in weight (kg) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on absolute change in weight

    Time frame: 68 weeks

  2. Achievement of at least 5 % body weight loss from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 5%

    Time frame: 68 weeks

  3. Achievement of at least 10% body weight loss from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 10%

    Time frame: 68 weeks

  4. Change in waist circumference (cm) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on waist circumference change

    Time frame: 68 weeks

  5. Percent change in triglycerides from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on triglycerides percent change

    Time frame: 68 weeks

  6. Change in systolic blood pressure (mmHg) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on systolic blood pressure change

    Time frame: 68 weeks

  7. Percent change in fat mass from baseline at 68 weeks of treatment measured by DXA in the DXA Sub-Study subset

    Body Composition Sub-study: To evaluate the effect of AZD6234 as compared to placebo on body composition change in the DXA subset of participants

    Time frame: 68 weeks

Who is running it

Lead sponsor
AstraZeneca
Sponsor type
Industry
Responsible party
The sponsor
Organisation
AstraZeneca
Data monitoring committee
No
US FDA-regulated drug
Yes
US FDA-regulated device
No
Sponsor's study ID
D8750C00014
Other IDs
2025-523379-41-00, 159494, 2025

Study sites(220)

  • Research Site

    Bhubaneswar, India

    Suspended

  • Research Site

    Coimbatore, India

    Not yet recruiting

  • Research Site

    Hyderabad, India

    Not yet recruiting

  • Research Site

    Indore, India

    Not yet recruiting

  • Research Site

    Jaipur, India

    Not yet recruiting

  • Research Site

    Jodhpur, India

    Not yet recruiting

  • Research Site

    Kochi, India

    Suspended

  • Research Site

    Kolkata, India

    Not yet recruiting

  • Research Site

    Noida, India

    Not yet recruiting

  • Research Site

    Pune, India

    Not yet recruiting

  • Research Site

    Pune, India

    Not yet recruiting

  • Research Site

    Siliguri, India

    Not yet recruiting

  • Research Site

    Surat, India

    Not yet recruiting

  • Research Site

    Vijayawada, India

    Not yet recruiting

  • Research Site

    Dothan, Alabama, United States

    Recruiting

  • Research Site

    Escondido, California, United States

    Recruiting

  • Research Site

    Clearwater, Florida, United States

    Recruiting

  • Research Site

    Stockbridge, Georgia, United States

    Recruiting

  • Research Site

    Champaign, Illinois, United States

    Recruiting

  • Research Site

    Chicago, Illinois, United States

    Recruiting

  • Research Site

    Ames, Iowa, United States

    Recruiting

  • Research Site

    Kansas City, Missouri, United States

    Recruiting

  • Research Site

    Rocky Mount, North Carolina, United States

    Recruiting

  • Research Site

    Statesville, North Carolina, United States

    Recruiting

  • Research Site

    Fargo, North Dakota, United States

    Recruiting

  • Research Site

    Columbus, Ohio, United States

    Recruiting

  • Research Site

    Tulsa, Oklahoma, United States

    Recruiting

  • Research Site

    Philadelphia, Pennsylvania, United States

    Recruiting

  • Research Site

    Smithfield, Pennsylvania, United States

    Recruiting

  • Research Site

    Kingsport, Tennessee, United States

    Recruiting

  • Research Site

    Houston, Texas, United States

    Recruiting

  • Research Site

    Sugar Land, Texas, United States

    Recruiting

  • Research Site

    Waco, Texas, United States

    Recruiting

  • Research Site

    Buenos Aires, Argentina

    Recruiting

  • Research Site

    Buenos Aires, Argentina

    Recruiting

  • Research Site

    Ciudad de Buenos Aires, Argentina

    Recruiting

  • Research Site

    Mendoza, Argentina

    Recruiting

  • Research Site

    Rosario, Argentina

    Recruiting

  • Research Site

    Botany, Australia

    Recruiting

  • Research Site

    Camberwell, Australia

    Recruiting

Showing 40 of 220 sites. 76 recruiting, 139 not recruiting and 5 cancelled; 14 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.

References and data sharing

Participant data shared
Yes
What is shared
Study protocol, Sap
When
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Source: ClinicalTrials.gov record NCT07784725, status verified October 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Take part

Interested in this study?

Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.

A person reads this, not a bot. We are not doctors, this is not medical advice, and it is not for emergencies.

Not the right study?

Every study recruiting in India, one search away.